Provocative gene therapy strategy for the treatment of hepatocellular carcinoma.
Askari
F
F
Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48105.
Wilson
J
J
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000378:metabolism / Q000627:therapeutic use*; D001711:Biotransformation; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D014645:Herpesvirus 3, Human / Q000235:genetics*; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D008114:Liver Neoplasms, Experimental / Q000628:therapy*; D011355:Prodrugs / Q000627:therapeutic use*; D012190:Retroviridae / Q000235:genetics*; D013937:Thymidine Kinase / Q000235:genetics* / Q000378:metabolism; D014162:Transfection
D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D011355:Prodrugs; C069956:6-methoxypurine arabinoside; D013937:Thymidine Kinase